Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

IntelGenx in feasibility pact with ATAI for film-based psychedelics

IntelGenx (TSXV:IGX; OTCQB:IGXT) and ATAI Life Sciences signed a feasibility agreement for the development of novel formulations of pharmaceutical-grade psychedelics, based on IntelGenx’s film technologies. Under...

August 20, 2020

Developments

Albireo Pharma ends development of elobixibat for NASH/NAFLD

Albireo Pharma (NASDAQ:ALBO) reported topline results from its Phase 2 trial evaluating elobixibat for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). The trial...

August 18, 2020

Developments

Vanda Pharma reports interim results from Phase 3 COVID-19 trial

Vanda Pharmaceuticals (NASDAQ:VNDA) reported interim results from its Phase 3 trial assessing tradipitant for the treatment of COVID-19 pneumonia. The data are based on the first 60 patients enrolled in the study, who...

August 18, 2020

Markets

SVB Leerink starts iTeos Therapeutics at OP; PT $36

SVB Leerink launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with an “outperform” rating and $36 price target. The stock closed at $32.92 on Aug. 18. “Though the stock has rallied since the IPO, we see potential...

August 18, 2020

Markets

Stifel starts Nurix Therapeutics at buy; PT $34

Stifel initiated coverage of Nurix Therapeutics (NASDAQ:NRIX) with a “buy” rating and $34 price target. The stock closed at $27 on Aug. 17. Nurix is a soon-to-be-clinical-stage company focused on the discovery...

August 18, 2020

Developments

Mustang Bio MB-107 gets FDA rare pediatric disease designation

The FDA granted Mustang Bio’s (NASDAQ:MBIO) MB-107 rare pediatric disease designation for the treatment of X-linked severe combined immunodeficiency. Patients with X-linked severe combined immunodeficiency produce...

August 17, 2020

Markets

Maxim ups TFF Pharma PT to $18 from $12

Maxim Group raised its price target for TFF Pharmaceuticals (NASDAQ:TFFP) to $18 from $12, citing a new partnership with Union Therapeutics that further validates TFF’s platform potential. The stock closed at $11.55 on...

August 17, 2020

Markets

HCW ups aTyr Pharma to buy; PT $13

H.C. Wainwright upgraded aTyr Pharma (NASDAQ:LIFE) to “buy” from “neutral” with a $13 price target, citing a “positive shift” at the company ahead of anticipated news flow. The stock closed at $3.81 on Aug. 14. Analyst...

August 17, 2020

Developments

Imara doses first patient in Phase 2b sickle cell disease trial

Imara (NASDAQ:IMRA) dosed the first patient in its Phase 2b Ardent trial evaluating IMR-687 for the treatment of sickle cell disease. The trial will enrol some 99 patients with sickle cell disease, who will receive...

August 13, 2020

Developments

Scholar Rock gets FDA rare pediatric disease designation for spinal muscular atrophy

Scholar Rock (NASDAQ:SRRK) received FDA rare pediatric disease designation for SRK-015 for the treatment of spinal muscular atrophy. Spinal muscular atrophy is a rare genetic disease that leads to motor function...

August 13, 2020

Developments

AzurRx BioPharma reports positive interim data from Phase 2 cystic fibrosis trial

AzurRx BioPharma (NASDAQ:AZRX) reported positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients...

August 12, 2020

Developments

FDA approves Lantheus’ VIALMIXRFID activation device

The FDA approved Lantheus’ (NASDAQ:LNTH) supplemental drug application for VIALMIXRFID, a device that activates the company’s DEFINITY injectable suspension. DEFINITY injectable suspension is an ultrasound imaging agent...

August 12, 2020

Subscribe